Consistent with this, our subsequent randomized, placebo-controlled trials revealed that eight weekly infusions of high-dose (40,000 IU) EPO vs. saline had mood-independent beneficial effects on cognitive function in patients with TRD (N = 40) and BD in remission (N = 44) [8, 9]. Here, EPO is linked to Behcet disease.